Saxenda: Underlying Mechanisms and Clinical Outcomes
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this protocol is to investigate the effect of treatment with the study drug
Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food
intake.